Evidence map›Paper›PMID 35743582›Full record

ArticleJournal of clinical medicine2022

Sensitization-Associated Post-COVID-19 Symptoms at 6 Months Are Not Associated with Serological Biomarkers at Hospital Admission in COVID-19 Survivors: A Secondary Analysis of a Cohort Study.

César Fernández-de-Las-Peñas, Manuel Herrero-Montes, Diego Ferrer-Pargada, Sheila Izquierdo-Cuervo, Lars Arendt-Nielsen, Jo Nijs, Paula Parás-Bravo

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

César Fernández-de-Las-PeñasDepartment of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), 28922 Madrid, Spain.ORCID 0000-0003-3772-9690
Manuel Herrero-MontesDepartamento de Enfermería, Universidad de Cantabria, 39008 Santander, Spain.ORCID 0000-0002-5732-8344
Diego Ferrer-PargadaServicio de Neumología, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
Sheila Izquierdo-CuervoServicio de Neumología, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
Lars Arendt-NielsenCNAP, Center for Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.ORCID 0000-0003-0892-1579
Jo NijsPain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education & Physiotherapy, Vrije Universiteit Brussel, 1050 Brussels, Belgium.ORCID 0000-0002-4976-6563
Paula Parás-BravoDepartamento de Enfermería, Universidad de Cantabria, 39008 Santander, Spain.ORCID 0000-0001-7745-3006
Marqués de Valdecilla University Hospital · ESUniversidad de Cantabria · ESAalborg University Hospital · DKUniversidad Rey Juan Carlos · ESVrije Universiteit Brussel · BE

Funding

Instituto de Investigación Marqués de Valdecilla Next-Val 2021Novo Nordisk Foundation NNF0067235
6 · The paper itself

Abstract

Individuals who survived coronavirus disease, 2019 (COVID-19), often have symptoms of sensitization, but the extent to which these symptoms relate to serological biomarkers remains unclear. Therefore, this secondary analysis evaluated the association between serological biomarkers at hospital admission with sensitization-associated post-COVID-19 symptoms in a sample of previously hospitalized COVID-19 survivors. Sixty-seven individuals hospitalized due to SARS-CoV-2 infection in one urban hospital of Madrid (Spain) during the first wave of the pandemic were assessed a mean of 6.0 (SD 0.8) months after hospital discharge. The Central Sensitization Inventory (CSI) was used as rough tool to estimate the presence of sensitization-associated post-COVID-19 symptoms (≥40/100 points). Levels of 16 serological biomarkers collected at hospital admission were obtained from medical records. Twenty-four (35.8%) patients reported sensitization-associated post-COVID-19 symptoms (CSI ≥ 40 points). Subjects reporting sensitization-associated symptoms had lower ferritin and hemoglobin levels than those not reporting sensitization-associated post-COVID-19 symptoms; however, these differences were small. We observed significant but small negative associations of the CSI score with ferritin (r: -0.251,

Indexed as

biomarkersCOVID-19hospitalizationpost-COVID-19sensitization

Identifiers

PMID35743582
PMCPMC9225549
OpenAlexW4283071642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.